EU approval for self-administered Crysvita
20th July 2021 Uncategorised 0Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
More: EU approval for self-administered Crysvita
Source: News
Crysvita is used to treat the rare genetic condition X-linked hypophosphataemia
More: EU approval for self-administered Crysvita
Source: News
© 1994 - 2025 B.M. Pharmaceuticals